|
KMID : 0939920210530041024
|
|
대한암학회지
2021 Volume.53 No. 4 p.1024 ~ p.1032
|
|
|
The Clinical Impact of Capmatinib in the Treatment of Advanced Non?Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
|
|
Choi Won-Young
Park Seog-Yun
Lee Young-Joo
Lim Kun-Young
Park Min-Joung
Lee Geon-Kook
Han Ji-Youn
|
|
|
Abstract
|
|
|
Purpose: Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non?small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation (METex14) or gene amplification.
Materials and Methods: Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study. MET gene copy number (GCN), protein expression, and METex14 were analyzed and the patients’ clinical outcome were retrospectively reviewed.
Results: A total of 72 patients were included in this analysis (group A: GCN ≥ 10 or METex14, n=14; group B: others, n=58). Among them, 13 patients were treated with capmatinib (group A, n=8; group B, n=5), and the overall response rate was 50% for group A, and 0% for group B. In all patients, the median overall survival (OS) was 20.2 months (95% confidence interval [CI], 6.9 to not applicable [NA]) for group A, and 11.3 months (95% CI, 8.2 to 20.3) for group B (p=0.457). However, within group A, median OS was 21.5 months (95% CI, 20.8 to NA) for capmatinib-treated, and 7.5 months (95% CI, 3.2 to NA) for capmatinib-untreated patients (p=0.025). Among all capmatinib-untreated patients (n=59), group A showed a trend towards worse OS to group B (median OS, 7.5 months vs. 11.3 months; p=0.123).
Conclusion: Our data suggest that capmatinib is a new compelling treatment for NSCLC with MET GCN ≥ 10 or METex14 based on the improved survival within these patients.
|
|
|
KEYWORD
|
|
|
Non-small-cell lung carcinoma, c-MET, Capmatinib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|